Skip to content
Home/Companies/Diagnostics/ZYTOMICS
ZYTOMICS

ZYTOMICS

Diagnostics·Germany·Active·6yr hold
Entry
2020
Hold
6yr
Status
Active

Who owns ZYTOMICS?

ZYTOMICS is currently owned by ARCHIMED through MED Platform I (2019 vintage), since 2020.

Hand-verified · updated 2026-04-21

ARCHIMED
Investor
ARCHIMED
MED Platform I · 2019 · Buyout

Key facts

HQGermany
SectorDiagnostics
Websitewww.zytomics.com

More from MED Platform I

Other portfolio companies in the same fund.

CARSO
Carso
Active
MedTechFrance· 2021
Ad-Tech Medical Instrument
Exited 2024
MedTechUS· 2020
to
Ametris (ActiGraph)
Ametris (ActiGraph)
Exited 2026
HealthTechUS· 2020
to
Namsa
Active
MedTechUS· 2020
Bomi Group
Exited 2023
MedTechItaly· 2019
to
Direct Healthcare Group
Exited 2026
MedTechUK· 2019
to

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Optos
Exited 2015
Amadeus Capital PartnersUK
to
Axomove
Axomove
Active
Go CapitalFrance· 2026
Bioliberty
Active
Scottish National Investment BankUK· 2026
CertHub
Active
Cusp Capital PartnersGermany· 2026
Clee Medical
Clee Medical
Active
High-Tech Gruenderfonds (HTGF)Switzerland· 2026
CollimateHealth
Active
Caesar Ventures ManagementGermany· 2026
Track Zytomics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Zytomics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue